Therapeutic Effect of Mongolian Medicine RuXian-I on Hyperplasia of Mammary Gland Induced by Estrogen/Progesterone through CRYAB-Promoted Apoptosis

Jia Liu; Jun-Fei Zhang; Guo-Hua Gong; Bin Zhang; Cheng-Xi Wei

doi:10.1155/2020/5707106

Therapeutic Effect of Mongolian Medicine RuXian-I on Hyperplasia of Mammary Gland Induced by Estrogen/Progesterone through CRYAB-Promoted Apoptosis

Evid Based Complement Alternat Med. 2020 May 27:2020:5707106. doi: 10.1155/2020/5707106. eCollection 2020.

Authors

Jia Liu¹, Jun-Fei Zhang², Guo-Hua Gong^{3

4

5}, Bin Zhang⁵, Cheng-Xi Wei^{3

4}

Affiliations

¹ Medical Experimental Center, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750000, China.
² Department of Emergency Medical, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750000, China.
³ Medicinal Chemistry and Pharmacology Institute, Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia, China.
⁴ Inner Mongolia Key Laboratory of Mongolian Medicine Pharmacology for Cardio-Cerebral Vascular System, Tongliao, Inner Mongolia, China.
⁵ Affiliated Hospital of Inner Mongolia University for Nationalities, Institute of Mongolia and Western Medicinal Treatment, Tongliao, Inner Mongolia, China.

Abstract

The traditional Mongolian medicine (TMM) RuXian-I is an empirical formula specifically used for treating the hyperplasia of mammary gland (HMG) in clinic based on the principles of traditional Mongolian medicine, but the treatment mechanism is not completely clear. In this paper, we elaborated the mechanism of RuXian-I in the treatment of HMG induced by estrogen and progestogen from its toxicity and activity. Firstly, RuXian-I exhibited no toxic effect on HMG rats through no changes of body weight and food intake measurement and no pathologic changes of the organs (heart, liver, spleen, lung, and kidney) detected. Secondly, RuXian-I could decrease the increased nipple height and diameter and remarkably relieve the pathologic changes of HMG rats and also alleviate serum sex hormone levels (estradiol (E₂), luteinizing hormone (LH), progesterone (P), and testosterone (T)) of HMG rats. Finally, RuXian-I could obviously inhibit the upregulation level of antiapoptotic protein CRYAB of HMG rats and promote mammary gland cell apoptosis of HMG rats via increases of promoting apoptosis protein caspases-3, 8, and 9 and Bax and tumor suppressor protein p53, decreases of antiapoptosis protein Bcl-2, and release of cytochrome c. These results suggested that RuXian-I has protective and therapeutic effects on HMG rats induced by estrogen and progestogen possibly via promoting apoptotic pathway regulated by CRYAB and is a promising agent for treating HMG.